Matches in SemOpenAlex for { <https://semopenalex.org/work/W1830209188> ?p ?o ?g. }
- W1830209188 endingPage "217" @default.
- W1830209188 startingPage "208" @default.
- W1830209188 abstract "Abstract Ibrutinib (Imbruvica ™ ) is an irreversible, potent inhibitor of Bruton's tyrosine kinase ( BTK ). Over the last few years, ibrutinib has developed from a promising drug candidate to being approved by FDA for the treatment of three B cell malignancies, a truly remarkable feat. Few, if any medicines are monospecific and ibrutinib is no exception; already during ibrutinib's initial characterization, it was found that it could bind also to other kinases. In this review, we discuss the implications of such interactions, which go beyond the selective effect on BTK in B cell malignancies. In certain cases, the outcome of ibrutinib treatment likely results from the combined inhibition of BTK and other kinases, causing additive or synergistic, effects. Conversely, there are also examples when the clinical outcome seems unrelated to inhibition of BTK . Thus, more specifically, adverse effects such as enhanced bleeding or arrhythmias could potentially be explained by different interactions. We also predict that during long‐term treatment bone homoeostasis might be affected due to the inhibition of osteoclasts. Moreover, the binding of ibrutinib to molecular targets other than BTK or effects on cells other than B cell‐derived malignancies could be beneficial and result in new indications for clinical applications." @default.
- W1830209188 created "2016-06-24" @default.
- W1830209188 creator A5034726240 @default.
- W1830209188 creator A5036357426 @default.
- W1830209188 creator A5036990093 @default.
- W1830209188 creator A5042513567 @default.
- W1830209188 creator A5049924304 @default.
- W1830209188 creator A5051993163 @default.
- W1830209188 creator A5056740658 @default.
- W1830209188 creator A5065902991 @default.
- W1830209188 creator A5070030873 @default.
- W1830209188 date "2015-08-18" @default.
- W1830209188 modified "2023-10-08" @default.
- W1830209188 title "Targets for Ibrutinib Beyond B Cell Malignancies" @default.
- W1830209188 cites W1264670492 @default.
- W1830209188 cites W1422422772 @default.
- W1830209188 cites W1497475008 @default.
- W1830209188 cites W1509735873 @default.
- W1830209188 cites W1517868493 @default.
- W1830209188 cites W1523413388 @default.
- W1830209188 cites W1528508275 @default.
- W1830209188 cites W1562437391 @default.
- W1830209188 cites W1801742181 @default.
- W1830209188 cites W1951217465 @default.
- W1830209188 cites W1964321121 @default.
- W1830209188 cites W1964550750 @default.
- W1830209188 cites W1964891050 @default.
- W1830209188 cites W1966408108 @default.
- W1830209188 cites W1966717237 @default.
- W1830209188 cites W1971597034 @default.
- W1830209188 cites W1976225087 @default.
- W1830209188 cites W1977054868 @default.
- W1830209188 cites W1977946844 @default.
- W1830209188 cites W1983530651 @default.
- W1830209188 cites W1986924929 @default.
- W1830209188 cites W1998096690 @default.
- W1830209188 cites W1999768094 @default.
- W1830209188 cites W2003164049 @default.
- W1830209188 cites W2007417599 @default.
- W1830209188 cites W2009904927 @default.
- W1830209188 cites W2010829192 @default.
- W1830209188 cites W2011960630 @default.
- W1830209188 cites W2016775461 @default.
- W1830209188 cites W2017372504 @default.
- W1830209188 cites W2019216438 @default.
- W1830209188 cites W2025707347 @default.
- W1830209188 cites W2026282548 @default.
- W1830209188 cites W2027648780 @default.
- W1830209188 cites W2028842451 @default.
- W1830209188 cites W2030245957 @default.
- W1830209188 cites W2033414663 @default.
- W1830209188 cites W2034013604 @default.
- W1830209188 cites W2037499635 @default.
- W1830209188 cites W2038413203 @default.
- W1830209188 cites W2039432759 @default.
- W1830209188 cites W2041055293 @default.
- W1830209188 cites W2049243830 @default.
- W1830209188 cites W2049595552 @default.
- W1830209188 cites W2050818562 @default.
- W1830209188 cites W2052690081 @default.
- W1830209188 cites W2053463045 @default.
- W1830209188 cites W2054220445 @default.
- W1830209188 cites W2054526083 @default.
- W1830209188 cites W2055221600 @default.
- W1830209188 cites W2057622523 @default.
- W1830209188 cites W2058932848 @default.
- W1830209188 cites W2059271361 @default.
- W1830209188 cites W2062482627 @default.
- W1830209188 cites W2063262989 @default.
- W1830209188 cites W2070308698 @default.
- W1830209188 cites W2071549499 @default.
- W1830209188 cites W2071773206 @default.
- W1830209188 cites W2073560673 @default.
- W1830209188 cites W2075675512 @default.
- W1830209188 cites W2075875145 @default.
- W1830209188 cites W2079501827 @default.
- W1830209188 cites W2079634050 @default.
- W1830209188 cites W2080558659 @default.
- W1830209188 cites W2080570985 @default.
- W1830209188 cites W2081964845 @default.
- W1830209188 cites W2082414447 @default.
- W1830209188 cites W2087139409 @default.
- W1830209188 cites W2089103836 @default.
- W1830209188 cites W2091347081 @default.
- W1830209188 cites W2096843911 @default.
- W1830209188 cites W2100034730 @default.
- W1830209188 cites W2102951716 @default.
- W1830209188 cites W2106837613 @default.
- W1830209188 cites W2107307057 @default.
- W1830209188 cites W2107773259 @default.
- W1830209188 cites W2107820445 @default.
- W1830209188 cites W2112297796 @default.
- W1830209188 cites W2113764179 @default.
- W1830209188 cites W2115086589 @default.
- W1830209188 cites W2123470487 @default.
- W1830209188 cites W2124458096 @default.
- W1830209188 cites W2131666890 @default.
- W1830209188 cites W2131823788 @default.